Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphomaMaarja‐Liisa Nairismägi, Jing Tan|Leukemia|2018Cited by 57